Skip to main content

Table 3 Patient-specific model parameters

From: How mathematical modeling could contribute to the quantification of metastatic tumor burden under therapy: insights in immunotherapeutic treatment of non-small cell lung cancer

 

Patient

KE-01

KE-02

KE-03

 

Parameter

Explanation

   

Origin

K

Environmental carrying capacity [cells]

1012

1012

1012

fixed, [26]

a

Growth rate [1/day]

7.284·10−3

6.877·10−3

6.984·10−3

fitted

  

(1.041·10−3)

(3.734·10−3)

(0.611·10−3)

 

m

Colonization coefficient [1/cell 1/day]

1.635·10−7

1.984·10−7

2.738·10−7

fitted

  

(0.157·10−7)

(3.816·10−7)

(0.490·10−7)

 

α

Fractal dimension of tumor cells able to metastasize [-]

2/3

2/3

2/3

fixed, [55]

 

Chemotherapeutic drug in use

CisPT/Pemet. (1L)

-

CisPT/Pemet. (1L)

Data

μ0

Initial chemotherapy efficiency [-]

0.237 (1.000)

-

0.081 (0.917)

fitted

μ∗

Refractory effect under chemotherapy application [-]

0.132 (1.000)

-

0.132 (1.321)

fitted

 

Immunotherapeutic drug in use

Pembr. (2L)

Nivol. (1L)

Pembr. (2L)

Data

χ

Immunotherapeutic effect under application [1/day]

0.067 (0.096)

0.499 (0.078)

0.088 (0.011)

fitted

\(c_{i}^{50}\)

Drug concentration of immunotherapeutic drug

1.012·1016

1.010·1016

1.009·1016

fitted

 

for half-maximal response [molecules per volume]

(0.142·1016)

(0.089·1016)

(0.020·1016)

 

\(c_{i}^{st}\)

Drug concentration of immunotherapeutic drug

1.41·1018

2.77·1018

1.41·1018

estimated,

 

in serum steady state [molecules per volume]

   

cf. Eq. (10)

T

Age of primary tumor at diagnosis [d]

407.1

272.2

336.5

estimated,

     

cf. Eq. (3)

TVDT

Tumor volume doubling time at diagnosis [d]

91.6

25.9

43.7

estimated,

     

cf. Eq. (4)

  1. CisPT/Pemet. = Combination therapy of Cisplatinum and Pemetrexed. Pembr. = Pembrolizumab. Nivol. = Nivolumab. (1L) = First-line therapy. (2L) = Second-line therapy. The values in brackets indicate the corresponding standard errors